Self-assembled squalenoyl-cytarabine nanostructures as a potent nanomedicine for treatment of leukemic diseases

References

• TallmanMSGillilandDGRoweJMDrug therapy for acute myeloid leukemiaBlood200510641154116315870183
   PubMed Web of Science ®Google Scholar
• TsurumiHKanemuraNHaraTTherapeutic strategy of untreated de novo acute myeloid leukemia in the elderly: the efficacy of continuous drip infusion with low dose cytarabine and etoposideJ Cancer Res Clin Oncol2007133854755317453240
   PubMed Web of Science ®Google Scholar
• RobakTWierzbowskaACurrent and emerging therapies for acute myeloid leukemiaClin Ther200931Pt 22349237020110045
   PubMed Web of Science ®Google Scholar
• GalmariniCMThomasXCalvoFPotential mechanisms of resistance to cytarabine in AML patientsLeuk Res200226762162912008078
   PubMed Web of Science ®Google Scholar
• BoletiHCoeIRBaldwinSAYoungJDCassCEMolecular identification of the equilibrative NBMPR-sensitive (es) nucleoside transporter and demonstration of an equilibrative NBMPR-insensitive (ei) transport activity in human erythroleukemia (K562) cellsNeuropharmacology1997369116711799364472
   PubMed Web of Science ®Google Scholar
• MichieliMDamianiDErmacoraAP-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implicationsBr J Haematol1999104232833510050716
   PubMed Web of Science ®Google Scholar
• HamadaAKawaguchiTNakanoMClinical pharmacokinetics of cytarabine formulationsClin Pharmacokinet2002411070571812162758
   PubMed Web of Science ®Google Scholar
• CelanoMSchenoneSCoscoDCytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivoEndocr Relat Cancer200815249951018509002
   PubMed Web of Science ®Google Scholar
• PaolinoDCoscoDLicciardiMGiammonaGFrestaMCavallaroGPolyaspartylhydrazide copolymer-based supramolecular vesicular aggregates as delivery devices for anticancer drugsBiomacromolecules2008941117113018307306
   PubMed Web of Science ®Google Scholar
• FontanaGManiscalcoLSchillaciDCavallaroGGiammonaGSolid lipid nanoparticles containing tamoxifen characterization and in vitro antitumoral activityDrug Deliv200512638539216253954
   PubMed Web of Science ®Google Scholar
• PaolinoDCoscoDRacanicchiLGemcitabine-loaded PEGylated unilamellar liposomes vs Gemzar: biodistribution, pharmacokinetic features and in vivo antitumor activityJ Control Release2010144214415020184929
   PubMed Web of Science ®Google Scholar
• LicciardiMPaolinoDCeliaCGiammonaGCavallaroGFrestaMFolate-targeted supramolecular vesicular aggregates based on polyaspartyl- hydrazide copolymers for the selective delivery of antitumoral drugsBiomaterials201031287340735420609469
   PubMed Web of Science ®Google Scholar
• BeneschMUrbanCLiposomal cytarabine for leukemic and lymphomatous meningitis: recent developmentsExpert Opin Pharmacother20089230130918201152
   PubMed Web of Science ®Google Scholar
• ParasoleRMennaGMarraNEfficacy and safety of intrathecal liposomal cytarabine for the treatment of meningeal relapse in acute lymphoblastic leukemia: experience of two pediatric institutionsLeuk Lymphoma20084981553155918766969
   PubMed Web of Science ®Google Scholar
• BeneschMSieglerNHoffKSafety and toxicity of intrathecal liposomal cytarabine (Depocyte) in children and adolescents with recurrent or refractory brain tumors: a multi-institutional retrospective studyAnticancer Drugs200920979479919617818
   PubMed Web of Science ®Google Scholar
• ReddyLHCouvreurPSqualene: A natural triterpene for use in disease management and therapyAdv Drug Deliv Rev200961151412142619804806
   PubMed Web of Science ®Google Scholar
• NewmarkHLSqualene, olive oil, and cancer risk: a review and hypothesisCancer Epidemiol Biomarkers Prev1997612110111039419410
   PubMed Web of Science ®Google Scholar
• SmithTJSqualene: potential chemopreventive agentExpert Opin Investig Drugs20009818411848
   PubMed Web of Science ®Google Scholar
• CouvreurPReddyLHMangenotSDiscovery of new hexagonal supramolecular nanostructures formed by squalenoylation of an anticancer nucleoside analogueSmall20084224725318247384
   PubMed Web of Science ®Google Scholar
• CouvreurPStellaBReddyLHSqualenoyl nanomedicines as potential therapeuticsNano Lett20066112544254817090088
   PubMed Web of Science ®Google Scholar
• CastelliFSarpietroMGCerutiMRoccoFCattelLCharacterization of lipophilic gemcitabine prodrug-liposomal membrane interaction by differential scanning calorimetryMol Pharm20063673774417140261
   PubMed Web of Science ®Google Scholar
• SarpietroMGMicieliDRoccoFCerutiMCastelliFConjugation of squalene to acyclovir improves the affinity for biomembrane modelsInt J Pharm20093821–2737919686827
   PubMed Web of Science ®Google Scholar
• VoyronSRoccoFCerutiMAntifungal activity of bisazasqualenes, inhibitors of oxidosqualene cyclaseMycoses201053648148719549106
   PubMed Web of Science ®Google Scholar
• CerutiMBallianoGRoccoFSynthesis and biological activity of new iodoacetamide derivatives on mutants of squalene-hopene cyclaseLipids200540772973516196424
   PubMed Web of Science ®Google Scholar
• BergmanAMPinedoHMJongsmaAPDecreased resistance to gemcitabine (2′,2′-difluorodeoxycitidine) of cytosine arabinoside-resistant myeloblastic murine and rat leukemia cell lines: role of altered activity and substrate specificity of deoxycytidine kinaseBiochem Pharmacol19995743974069933028
   PubMed Web of Science ®Google Scholar
• MudhakirDAkitaHKhalilIAFutakiSHarashimaHPharmacokinetic analysis of the tissue distribution of octa-arginine modified liposomes in miceDrug Metab Pharmacokinet200520427528116141607
   PubMedGoogle Scholar
• GabizonAPriceDCHubertyJBresalierRSPapahadjopoulosDEffect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studiesCancer Res19905019637163781698120
   PubMed Web of Science ®Google Scholar
• BildsteinLDubernetCMarsaudVTransmembrane diffusion of gemcitabine by a nanoparticulate squalenoyl prodrug: an original drug delivery pathwayJ Control Release2010147216317020691740
   PubMed Web of Science ®Google Scholar
• ReddyLHKhouryHPaciASqualenoylation favorably modifies the in vivo pharmacokinetics and biodistribution of gemcitabine in miceDrug Metab Dispos20083681570157718474674
   PubMed Web of Science ®Google Scholar
• DamarajuVLDamarajuSYoungJDNucleoside anticancer drugs: the role of nucleoside transporters in resistance to cancer chemotherapyOncogene200322477524753614576856
   PubMed Web of Science ®Google Scholar
• ReddyLHDubernetCMouelhiSLMarquePEDesmaeleDCouvreurPA new nanomedicine of gemcitabine displays enhanced anticancer activity in sensitive and resistant leukemia typesJ Control Release20071241–2202717878060
   PubMed Web of Science ®Google Scholar
• ReddyLHRenoirJMMarsaudVLepetre-MouelhiSDesmaëleDCouvreurPAnticancer efficacy of squalenoyl gemcitabine nanomedicine on 60 human tumor cell panel and on experimental tumorMol Pharm2009651526153519634915
   PubMed Web of Science ®Google Scholar
• ReddyLHMarquePEDubernetCMouelhiSLDesmaëleDCouvreurPPreclinical toxicology (subacute and acute) and efficacy of a new squalenoyl gemcitabine anticancer nanomedicineJ Pharmacol Exp Ther2008325248449018258784
   PubMed Web of Science ®Google Scholar
• WankoSOde CastroCHairy cell leukemia: an elusive but treatable diseaseOncologist200611778078916880237
   PubMed Web of Science ®Google Scholar
• StrandbergTETilvisRSMiettinenTAMetabolic variables of cholesterol during squalene feeding in humans: comparison with cholestyramine treatmentJ Lipid Res1990319163716432246614
   PubMed Web of Science ®Google Scholar